XENE
Xenon Pharmaceuticals Inc.
Biotechnology
Market Cap$4.42B
5Y Perf.+308.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XENE vs ARVN
Revenue, margins, valuation, and 5-year total return — side by side.
ARVN
Arvinas, Inc.
Biotechnology
Market Cap$652M
5Y Perf.-69.4%
XENE vs ARVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XENE | ARVN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $4.42B | $652M |
| Revenue (TTM) | $0.00 | $263M |
| Net Income (TTM) | $-383M | $-81M |
| Gross Margin | 66.1% | 99.5% |
| Operating Margin | -49.7% | -44.0% |
| Total Debt | $8M | $9M |
| Cash & Equiv. | $199M | $143M |
XENE vs ARVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XENE
ARVN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Xenon Pharmaceutica… (XENE) | 100 | 408.8 | +308.8% |
| Arvinas, Inc. (ARVN) | 100 | 30.6 | -69.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XENE vs ARVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ARVN leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Xenon Pharmaceuticals Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
XENE
Xenon Pharmaceuticals Inc.
The Income Pick
XENE is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.05
- 7.4% 10Y total return vs ARVN's -36.5%
- Lower volatility, beta 1.05, Low D/E 1.4%, current ratio 13.42x
Best for: income & stability and long-term compounding
ARVN
Arvinas, Inc.
The Growth Play
ARVN carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth -0.3%, EPS growth 53.8%, 3Y rev CAGR 26.0%
- -0.3% revenue growth vs XENE's -100.0%
- -30.8% margin vs XENE's -46.1%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARVN | -0.3% revenue growth vs XENE's -100.0% |
| Quality / Margins | ARVN | -30.8% margin vs XENE's -46.1% |
| Stability / Safety | XENE | Beta 1.05 vs ARVN's 1.15, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | XENE | +58.5% vs ARVN's +52.8% |
| Efficiency (ROA) | ARVN | -9.3% ROA vs XENE's -42.0%, ROIC -22.4% vs -55.3% |
XENE vs ARVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
FY 2025
XENE vs ARVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARVNLAGGINGXENE
XENEXenon Pharmaceuticals…
2leads
ARVNArvinas, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs XENEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARVN5/6
Valuation MetricsMultiples, price ratios, and targets
ARVN2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARVN4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
XENE6/6
Risk & VolatilityBeta, volatility, and downside exposure
XENE2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ARVN leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ARVN and XENE operate at a comparable scale, with $263M and $0 in trailing revenue. ARVN is the more profitable business, keeping -30.8% of every revenue dollar as net income compared to XENE's -46.1%. On growth, ARVN holds the edge at -84.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | XENEXenon Pharmaceuti… | ARVNArvinas, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $263M |
| EBITDAEarnings before interest/tax | -$411M | -$111M |
| Net IncomeAfter-tax profit | -$383M | -$81M |
| Free Cash FlowCash after capex | -$307M | -$276M |
| Gross MarginGross profit ÷ Revenue | +66.1% | +99.5% |
| Operating MarginEBIT ÷ Revenue | -49.7% | -44.0% |
| Net MarginNet income ÷ Revenue | -46.1% | -30.8% |
| FCF MarginFCF ÷ Revenue | -37.3% | -105.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | -84.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -41.0% | -65.1% |
ARVN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
ARVN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | XENEXenon Pharmaceuti… | ARVNArvinas, Inc. |
|---|---|---|
| Market CapShares × price | $4.4B | $652M |
| Enterprise ValueMkt cap + debt − cash | $4.2B | $517M |
| Trailing P/EPrice ÷ TTM EPS | -12.84x | -7.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 589.47x | 2.48x |
| Price / BookPrice ÷ Book value/share | 7.63x | 1.52x |
| Price / FCFMarket cap ÷ FCF | — | — |
ARVN leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ARVN leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
ARVN delivers a -14.3% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-49 for XENE. XENE carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARVN's 0.02x.
| Metric | XENEXenon Pharmaceuti… | ARVNArvinas, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -49.2% | -14.3% |
| ROA (TTM)Return on assets | -42.0% | -9.3% |
| ROICReturn on invested capital | -55.3% | -22.4% |
| ROCEReturn on capital employed | -43.8% | -16.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.02x |
| Net DebtTotal debt minus cash | -$191M | -$134M |
| Cash & Equiv.Liquid assets | $199M | $143M |
| Total DebtShort + long-term debt | $8M | $9M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ARVN leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
XENE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XENE five years ago would be worth $30,254 today (with dividends reinvested), compared to $1,601 for ARVN. Over the past 12 months, XENE leads with a +58.5% total return vs ARVN's +52.8%. The 3-year compound annual growth rate (CAGR) favors XENE at 9.6% vs ARVN's -25.5% — a key indicator of consistent wealth creation.
| Metric | XENEXenon Pharmaceuti… | ARVNArvinas, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +25.9% | -11.2% |
| 1-Year ReturnPast 12 months | +58.5% | +52.8% |
| 3-Year ReturnCumulative with dividends | +31.8% | -58.7% |
| 5-Year ReturnCumulative with dividends | +202.5% | -84.0% |
| 10-Year ReturnCumulative with dividends | +737.1% | -36.5% |
| CAGR (3Y)Annualised 3-year return | +9.6% | -25.5% |
XENE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
XENE leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XENE is the less volatile stock with a 1.05 beta — it tends to amplify market swings less than ARVN's 1.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XENE currently trades 87.6% from its 52-week high vs ARVN's 70.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XENEXenon Pharmaceuti… | ARVNArvinas, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.05x | 1.15x |
| 52-Week HighHighest price in past year | $63.95 | $14.51 |
| 52-Week LowLowest price in past year | $28.19 | $5.90 |
| % of 52W HighCurrent price vs 52-week peak | +87.6% | +70.2% |
| RSI (14)Momentum oscillator 0–100 | 61.3 | 42.6 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 808K |
XENE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates XENE as "Buy" and ARVN as "Buy". Consensus price targets imply 43.2% upside for XENE (target: $80) vs 27.6% for ARVN (target: $13).
| Metric | XENEXenon Pharmaceuti… | ARVNArvinas, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $80.20 | $13.00 |
| # AnalystsCovering analysts | 22 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +14.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARVN leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). XENE leads in 2 (Total Returns, Risk & Volatility).
Best OverallArvinas, Inc. (ARVN)Leads 3 of 6 categories
Loading custom metrics...
XENE vs ARVN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is XENE or ARVN a better buy right now?
Analysts rate Xenon Pharmaceuticals Inc.
(XENE) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XENE or ARVN?
Over the past 5 years, Xenon Pharmaceuticals Inc.
(XENE) delivered a total return of +202. 5%, compared to -84. 0% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: XENE returned +737. 1% versus ARVN's -36. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XENE or ARVN?
By beta (market sensitivity over 5 years), Xenon Pharmaceuticals Inc.
(XENE) is the lower-risk stock at 1. 05β versus Arvinas, Inc. 's 1. 15β — meaning ARVN is approximately 9% more volatile than XENE relative to the S&P 500. On balance sheet safety, Xenon Pharmaceuticals Inc. (XENE) carries a lower debt/equity ratio of 1% versus 2% for Arvinas, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — XENE or ARVN?
On earnings-per-share growth, the picture is similar: Arvinas, Inc.
grew EPS 53. 8% year-over-year, compared to -44. 9% for Xenon Pharmaceuticals Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — XENE or ARVN?
Arvinas, Inc.
(ARVN) is the more profitable company, earning -30. 8% net margin versus -46. 1% for Xenon Pharmaceuticals Inc. — meaning it keeps -30. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARVN leads at -43. 8% versus -49. 7% for XENE. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — XENE or ARVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is XENE or ARVN better for a retirement portfolio?
For long-horizon retirement investors, Xenon Pharmaceuticals Inc.
(XENE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 05), +737. 1% 10Y return). Both have compounded well over 10 years (XENE: +737. 1%, ARVN: -36. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between XENE and ARVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(XENE: -100.0% · ARVN: -84.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.